CASI Pharmaceuticals, Inc. — Form D

CASI Pharmaceuticals, Inc. of BEIJING, F4, a company, filed a Form D exempt-offering notice with the SEC on 2026-02-26. The offering totals $5.0M, of which $5.0M was reported sold. Industry: Pharmaceuticals.

Offering

Issuer

Officers, directors & promoters (36)

Showing 25 of 36 people.

NameRoleLocation
David A. CoryDirectorSouth San Francisco, CA
James A. HuangDirectorSouth San Francisco, CA
Barbara A. Krebs-PohlDirectorSouth San Francisco, CA
Alexander Y. WuDirectorRockville, MD
Xuebo Y. ZengDirectorBeijing, F4
David A. CoryExecutive OfficerSouth San Francisco, CA
Wei Y. GaoExecutive OfficerBeijing, F4
Hai Y. HuangExecutive OfficerBeijing, F4
Kun Y. QianExecutive OfficerBeijing, F4
Chunhua Y. WangExecutive OfficerBeijing, F4
Wei (Larry) Y. ZhangExecutive OfficerSouth San Francisco, CA
Alexander A. ZukiwskiExecutive OfficerSouth San Francisco, CA
Wei-Wu HeDirectorRockville, MD
Wei-Wu HeExecutive OfficerRockville, MD
Wei-Wu HeRelated PersonRockville, MD
James HuangRelated PersonSouth San Francisco, CA
Chunhua Y WangExecutive OfficerBeijing, F4
Wei Y GaoExecutive OfficerBeijing, F4
Alexander Y WuDirectorRockville, MD
Zhenbo SuDirectorBeijing, F4
Zhenbo SuRelated PersonBeijing, F4
Hai Y HuangExecutive OfficerBeijing, F4
Kun Y QianExecutive OfficerBeijing, F4
Thomas FolinsbeeDirectorBeijing, F4
Thomas FolinsbeeRelated PersonBeijing, F4

Other filings by this issuer (4)

FiledFormOfferingSold
2026-04-28D$5.0M$5.0M
2026-01-28D$5.0M$5.0M
2026-01-28D$5.0M$5.0M
2024-07-15D$15.0M$15.0M

More